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ABSTRACT 
Objective: To develop and validate a new and easy zero-crossing derivative method for the simultaneous determination of ketoprofen and 
acetaminophen in fixed-dose combination formulations and to demonstrate its application in dissolution studies. 
Methods: Measurement was achieved using the first derivative signals at 243.2 nm for ketoprofen and at 260.5 nm for acetaminophen. The method 
was validated according to ICH guidelines. The proposed method was applied for the simultaneous quantification of both drugs in samples taken 
during the study of dissolution profiles (USP Apparatus 2, 75 rpm and 900 ml of 0.1 M phosphate buffer pH 7.4) of Bifebral® reference product 
(100/300 mg ketoprofen and acetaminophen, respectively). Samples were also analyzed by a previously validated HPLC-PDA method. Dissolution 
profiles were compared by similarity factor f2. Additionally values of: t50%, t85%
Results: The first derivative spectrophotometric method was linear in the range of 25–200 µg/ml for ketoprofen and 25–150 µg/ml for 
acetaminophen (R
, dissolution efficiency and mean dissolution time, obtained for 
ketoprofen and acetaminophen using UV and HPLC-PDA methods, were compared by Student’s t-test. 
2>0.99, *P<0.05). The within-day and between-day precision and accuracy were within the acceptable criteria (RSD<3.4% and 
100±3%). Similarity factor f2
Conclusion: The proposed method can be used for the simultaneous determination of ketoprofen and acetaminophen, from fixed-dose combination 
formulations, in dissolution studies. The method is rapid, simple, accurate, and precise without the need of high-cost investment. 
 was 85.85 and 88.49 for ketoprofen and acetaminophen, respectively. No significant differences between data 
obtained with UV and HPLC-PDA methods were found (*P>0.05). 
Keywords: Ketoprofen, Acetaminophen, Derivative spectroscopy, Zero-crossing method, Dissolution studies. 
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INTRODUCTION 
Ketoprofen in a non-steroidal anti-inflammatory drug (NSAID) 
with analgesic, anti-inflammatory, and antipyretic properties [1]. 
Acetaminophen (also named as paracetamol) has analgesic and 
antipyretic properties as well as weak anti-inflammatory activity 
[2]. The combination of both drugs is used in the symptomatic 
management of postoperative pain [3, 4]. Previous reports 
suggest that a combination of acetaminophen with a NSAID may 
enhance analgesia compared with the effect produced by the 
drugs given alone [5, 6]. Chemical structures of both drugs are 
presented in fig. 1. 
 
 
Fig. 1: Chemical structures of ketoprofen (left) and 
acetaminophen (right) 
 
In Mexico, as in other parts of the world, immediate-release oral 
dosage forms containing ketoprofen and acetaminophen in fixed-
dose formulations are widely marketed as generic products. 
Therefore, between commercial lots or in the development of a new 
formulation, dissolution studies are essential for quality control 
purposes. However, to date, no official dissolution test for 
ketoprofen and acetaminophen marketed as fixed-dose combination 
formulations is described in the United States or Mexican 
Pharmacopeia [7, 8]. 
Simultaneous determination of drugs in pharmaceutical products is 
currently performed by high-performance liquid chromatography 
(HPLC). Chromatography usually requires time-consuming methods, 
toxic solvents, and expensive equipment. On the other hand and as 
an alternative technique, derivative spectrophotometry has gained 
widely acceptance as an analytical tool for quantification of drugs 
mixtures. Derivative spectrophotometry is a useful technique for the 
suppression of additive interferences due to compounds with 
overlapping spectra. As acetaminophen is a widely used compound, 
some derivative methods to determine acetaminophen combined 
with other drugs (aceclofenac, drotaverine, ibuprofen, aspirin, 
salicylic acid, caffeine, ascorbic acid, and tramadol) have been 
previously published [9-12] but none derivative spectrophotometric 
method for the combination of ketoprofen and acetaminophen has 
been reported. 
The main objective of this study was to develop and validate a 
simple, economic, and rapid zero-crossing first-derivative (1
MATERIALS AND METHODS 
D) 
spectrophotometric method for the simultaneous determination of 
ketoprofen and acetaminophen in fixed-dose combination 
formulations. The method was applied to evaluate the dissolution 
profiles of marketed products containing both drugs. Results were 
compared with those obtained by an HPLC-photo diode array (PDA) 
detector analysis. 
Materials 
Ketoprofen and acetaminophen standards were purchased from 
Sigma-Aldrich Co. (St. Louis MO, USA). Dissolution samples were 
filtered through 0.45 µm nitrocellulose Millipore® filters. Sodium 
phosphate monobasic and dibasic crystals, as well as methanol and 
acetonitrile HPLC grade, were purchased from J. T. Baker-Mexico. 
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The fixed-dose combination formulation containing ketoprofen and 
acetaminophen (100/300 mg respectively) used was Bifebral®
Content uniformity and assay 
 
(Sanofi-Aventis de México, S. A. de C. V., Mexico). Mexican health 
authorities have established this brand as reference product [13]. 
Content uniformity and assay tests were performed by a previously 
validated HPLC-PDA method. 
Standard solutions 
Stock solutions of ketoprofen and acetaminophen (1 mg/ml) in 0.1 
M phosphate buffer pH 7.4 were separately prepared. Standard 
solutions were prepared by serial dilutions of the stock solutions to 
contain the required concentrations for the calibration curves. 
Ketoprofen and acetaminophen calibration curves in 0.1 M 
phosphate buffer pH 7.4 were prepared in the concentration range 
of 25–200 µg/ml and 25–150 µg/ml, respectively. 
Instruments 
Dissolution studies were performed in a USP Apparatus 2 (Sotax AT-
7 Smart, Switzerland) using a piston pump (Sotax CY7-50, 
Switzerland). Ketoprofen and acetaminophen intact tablets were 
added on 900 ml of 0.1 M phosphate buffer pH 7.4 at 37.0±0.5ºC as 
dissolution medium (n=12). The rotational speed of 75 rpm was 
tested. After addition of tablets, 5 ml of filtered dissolution sample 
was withdrawn at 5, 10, 20, 30 and 45 min. For spectrophotometric 
measurement, a double beam UV/VIS spectrophotometer (Perkin 
Elmer Lambda 35, Waltham MA, USA) with 0.1 cm quartz cells was 
utilized. The operating conditions for UV analysis were 1
HPLC-PDA analysis was performed on an Agilent infinity 1260 
series, equipped with a quaternary pump, an autosampler, a column 
oven, and a PDA detector (Agilent, Waldbronn Germany). An 
Accucore C8 column (4.6 × 50 mm, 2.6 µm particle size) purchased 
from Thermo Scientific was used. The mobile phase consisted of 
water with 0.04 % of phosphoric ac. (v/v) (A), acetonitrile (B), and 
methanol (C). Separation was achieved by a gradient elution (0 min: 
80% A, 5% B, 15% C maintained 1.5 min), (2.5 min: 40% A, 40% B, 
20% C maintained for 3.5 min), (7.0 min: initial conditions), with a 
flow rate of 1.0 ml/min, 40 °C oven temperature, injection volume of 
5 µl and detection wavelength at 250 nm. 
D mode with 
scan speed 240 nm/min, slit width 2.0 nm and sampling interval 1.0 nm. 
Analytical method validation 
The proposed analytical method was validated according to the 
International Conference on Harmonization (ICH) guidelines [14]. 
System linearity, accuracy, precision, and stability were determined. 
Linearity 
To verify the methodʼs linearity in the concentration range studied, 
three series of calibration curves in 0.1 M phosphate buffer pH 7.4 
for ketoprofen and acetaminophen were determined. Then, 1
Accuracy and precision 
D 
response at certain wavelength was recorded. Data obtained were 
fitted by linear regression analysis and the coefficients of regression 
and regression analysis of variance (ANOVA) were calculated. The 
response vs. concentration drug proportionality was demonstrated 
for each drug by calculating the percentage relative standard 
deviation (RSD): [((standard deviation)/mean) × 100] of the 
response factor across the entire range of the calibration curve. 
In order to verify the accuracy and precision of the proposed 1
Stability 
D 
analysis, the added standard method was used, thus, matrix effects 
can easily be removed. This method can be used for resolving binary 
mixtures in complex samples with unknown matrices as fixed-dose 
combination formulations have. Twenty tablets were accurately 
weighed and crushed in a mortar; then, quantities of powder of 
ketoprofen and acetaminophen tablets plus a quantity of ketoprofen 
or acetaminophen standard (10 mg) to finally give the equivalent of 
80, 100 and 120% of the dose of each drug, were separately 
dissolved in 900 ml of 0.1 M phosphate buffer pH 7.4 at 37.0±0.5 °C. 
For this purpose, USP Apparatus 2 at 75 rpm was used. At 45 min, 
the amounts of ketoprofen and acetaminophen dissolved in each 
sample were calculated with reference to a calibration curve 
prepared on the day of the experiment. Each determination was 
performed in triplicate. The relative percentage error (RE): 
[((found–added)/added) × 100] was taken as a measure of the 
accuracy and the RSD as a measure of precision. Experiments were 
carried out in three consecutive days. 
Stability of analytical solutions was evaluated analyzing a solution of 
ketoprofen (30 µg/ml) and a solution of acetaminophen (128 µg/ml) 
in 0.1 M phosphate buffer pH 7.4. These solutions were analyzed by 
the proposed 1
Data analysis 
D method at 0, 24 and 48 h after stored at 4ºC. At 24 
and 48 h, the percentage absolute difference AD: [((initial–
final)/initial) × 100] recovered of each drug was determined. 
Dissolution profiles of ketoprofen and acetaminophen obtained with 
the proposed 1D method and by HPLC analysis were compared with 
similarity factor f2 [15]. Additionally, dissolution profiles of each 
drug were compared by model-dependent and independent 
methods [16]. For model-dependent comparisons, dissolution data 
were fitted to the hyperbola equation: y = ax/(b+x) using Sigma 
Plot software (Version 11.0). With a and b parameters values of 
t 50% and t85%
RESULTS AND DISCUSSION 
 were calculated. Dissolution efficiency (DE) and 
mean dissolution time (MDT) values were used for model-
independent comparisons [17]. For obtaining DE and MDT values, 
DD Solver add-in program was used [18]. Finally for data 
comparisons, Student’s t-test was used. Differences were 
considered significant if *P<0.05. 
Content uniformity and assay 
The reference product met the content uniformity and assay 
standard criteria. The percentages of ketoprofen and acetaminophen 
on the content uniformity test ranged from 85 to 115% and the 
assay test was between 90 and 110%, table 1. 
 
Table 1: Content uniformity and assay results, Ketoprofen (K) 
and acetaminophen (A) 
Drug Content uniformity (min–max) Assay (%) 
K 98.3–107.8 104.7±2.93 
A 98.3–104.0 101.6±2.21 
 Data are expressed as mean±standard deviation (n=10). 
 
Absorption spectra 
The zero-order spectra of ketoprofen (100 µg/ml) and 
acetaminophen (75 µg/ml) standard solutions in 0.1 M phosphate 
buffer pH 7.4 were measured alone or mixed at 200–320 nm using 
0.1 M phosphate buffer pH 7.4 as blank, fig. 2a. The zero-order 
spectra demonstrated a marked overlapping.  
As a result, simultaneous direct spectroscopy determination of 
ketoprofen and acetaminophen in fixed-dose combination 
formulations was not possible. Then, the 1D spectra of these 
solutions were obtained, fig. 2b. As seen in fig. 2b, the 1
The 
D spectra of 
ketoprofen and acetaminophen revealed four zero-crossing points 
for their simultaneous determination; these points were to be 216.3 
and 243.2 nm for ketoprofen and 234.0 and 260.5 nm for 
acetaminophen. 
1D spectra of ketoprofen (25–200 µg/ml) and acetaminophen 
(25–150 µg/ml) standard solutions were determined, fig. 3. The 
suitable zero-crossing points were selected based on the best linear 
response to the ketoprofen concentration in the presence of 
acetaminophen or the acetaminophen concentration in the presence 
of ketoprofen. Only the 1D response at 243.2 and 260.5 nm were 
proportional to the ketoprofen and acetaminophen concentrations, 
respectively. 
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Fig. 2: Zero-order spectra of (a) 100 µg/ml of ketoprofen (K), 75 
µg/ml of acetaminophen (A) and their mixture (K+A) at the 
same concentrations and (b) first-derivative spectra of the 
same solutions. Lines indicate zero-crossing points 
 
 
Fig. 3: First-derivative spectra of 25–200 µg/ml of ketoprofen 
(K) and 25–150 µg/ml of acetaminophen (A). Lines indicate 
243.2 and 260.5 nm, respectively 
Method validation 
Linearity 
The mean regression equation from three standard calibration curves 
was: y =–0.002x+0.001 for ketoprofen and y = 0.0024x+0.0012 for 
acetaminophen. Both linear regressions were significant (R2
Accuracy and precision 
=0.999; 
*P<0.05). The RSD values of response factor were 2.7 and 1.6% for 
ketoprofen and acetaminophen ranges, respectively. 
In order to prove the accuracy and precision of the proposed 1
Stability 
D 
method, analysis of varying percentage of a dose of each drug was 
carried out for three days (n=3/d). The within-day and between-day 
precision and accuracy were calculated, and results are shown in 
table 2. The RSD obtained was in the range of 0.37–3.45% and the RE 
was lower than 2.84% for both drugs in all selected dose percentages 
which indicate good accuracy and precision of the method. 
The stability of both drugs in 0.1 M phosphate buffer pH 7.4 was 
assessed analyzing one solution of ketoprofen and one solution of 
acetaminophen at different times. The absolute difference at 24 and 48 h 
are shown in table 3. As seen in table 3, ketoprofen solution was less 
stable. 
Results indicate that the proposed 1D method, for simultaneous 
determination of ketoprofen and acetaminophen in fixed-dose 
combination formulations, is linear, accurate, and precise. According 
to complementary ICH guideline [19], limit of detection and limit of 
quantitation are characteristics not normally evaluated in 
dissolutions assays. For both drugs, lack of linearity, accuracy, and 
precision was found at concentrations out of the proposed ranges of 
the calibration curves. 
Dissolution profiles 
Ketoprofen and acetaminophen dissolution profiles of reference 
product were obtained according to the procedure previously 
described. Dissolution samples were analyzed by the proposed 1D 
method and the HPLC-PDA analysis. Results are shown in fig. 4. 
As can be seen in fig. 4, dissolution profiles of ketoprofen and 
acetaminophen obtained with both analytical methods (UV and 
HPLC) were superimposable. For ketoprofen and acetaminophen, f2 
values were 85.85 and 88.49, respectively. Dissolution profiles are 
considered similar when f2
Model-dependent and independent parameters: t
 values are 50-100 [15]. 
50%, t85%, DE, and 
MDT calculated to compare dissolution profiles of ketoprofen and 
acetaminophen are shown in table 4. No significant differences were 
found (*P>0.05) between data obtained with the proposed 1
 
D 
method and HPLC-PDA analysis. 
Table 2: Accuracy and precision data for simultaneous determination of ketoprofen (K) and acetaminophen (A) by the proposed 1
 
D method 
 Within-day Between-day 
Drug/dose (mg) Added (mg) Found  (mg) RSD (%) RE (%) Found (mg) RSD (%) RE (%) 
K/100 80.47 81.80±0.62 0.75 1.65 82.76±1.80 2.18 2.84 
100.17 101.31±1.68 1.65 1.14 102.01±1.46 1.43 1.84 
120.56 122.22±0.45 0.37 1.38 122.66±1.09 0.89 1.75 
A/300 242.21 237.4±3.16 1.33 -1.99 242.20±7.77 3.21 0.0 
307.0 304.09±9.05 2.98 -0.95 308.25±10.63 3.45 0.41 
367.49 368.64±8.95 2.43 0.31 368.17±6.36 1.73 0.18 
 Data are expressed as mean±standard deviation (within-day n=3; between-day n=9). 
 
Table 3: Absolute difference (%) respect zero time to evaluate stability at 4 °C of ketoprofen (K) and acetaminophen (A) in 0.1 M 
phosphate buffer pH 7.4 
Drug Conc. (µg/ml) 24 h 48 h 
K 30.6 0.14 0.77 
A 128.4 1.19 1.59 
 Data are expressed as mean (n=8). 
Medina et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 2, 244-248 
 
247 
Table 4: Results to compare dissolution profiles of ketoprofen (K) and acetaminophen (A) 
Drug Analytical method Model-dependent Model-independent 
  t50% t (min) 85% DE (%)  (min) MDT (min) 
K UV 6.76±0.12 20.17±0.37 78.87±0.50 9.27±0.13 
HPLC 7.08±0.04 20.31±0.08 78.80±0.10 9.75±0.05 
A UV 7.20±0.15 21.05±0.37 77.77±0.47 9.78±0.16 
HPLC 7.43±0.03 21.30±0.06 77.52±0.09 9.97±0.05 
 Data are expressed as mean±standard error mean (n=12). 
 
 
Fig. 4: Dissolution profiles of ketoprofen and acetaminophen obtained with the 1
 
D spectrophotometric methods (UV) and 
chromatographic analysis (HPLC). Data are expressed as mean, n=12. Error bars were omitted for clarity 
As none derivative spectrophotometric method for the simultaneous 
determination of ketoprofen and acetaminophen in fixed-dose 
combination formulations has been reported, we consider that the 
results obtained are adequate for the previously defined purposes. 
The results suggest that the1D spectrophotometric method could be 
applied with great success for the simultaneous determination of 
ketoprofen and acetaminophen without the interference of each 
other and the matrix effect. The most striking feature of the 
proposed 1
CONCLUSION 
D method is its simplicity and rapidity. The method does 
not require time-consuming sample preparation such as filtration, 
degassing or using toxic solvents as methanol or acetonitrile that are 
commonly used in HPLC analysis. 
It was concluded that the zero-crossing 1
CONFLICT OF INTERESTS 
D spectroscopic method 
could be used for simultaneous determination of ketoprofen and 
acetaminophen in fixed-dose combination formulations. This 
method could be used for the analysis of active pharmaceutical 
ingredients in dissolution studies or for routine quality control 
analysis. The method is rapid, simple, and economical without the 
need of high-cost investment. 
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